Method for detecting conditions indicative of sepsis

• US 20030100122A1
• Filed: 08/22/2002
• Published: 05/29/2003
• Est. Priority Date: 09/19/2001
• Status: Active Grant

• Current Assignee: Washington University In St Louis
• Original Assignee: Washington University In St Louis
• Inventors: Heinecke, Jay W.
• Granted Patent: US 6,939,716 B2
• Time in Patent Office: Days
• US Class Current: 436/89
• CPC Class Codes: G01N 2030/025 Gas chromatography
• CPC Class Codes: G01N 30/7206 interfaced to gas chromatograph interfaces in general for introducing or extracting samples to be analysed with specially adapted mass spectrometer, see H01J49/04
• CPC Class Codes: G01N 33/5308 for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites
• CPC Class Codes: G01N 33/6812 Assays for specific amino acids
• CPC Class Codes: Y10S 436/811 Test for named disease, body condition or organ function
• CPC Class Codes: Y10T 436/173845 Amine and quaternary ammonium
• CPC Class Codes: Y10T 436/24 Nuclear magnetic resonance, electron spin resonance or other spin effects or mass spectrometry

Abstract

The disclosure describes a method for detecting conditions indicative of sepsis. In one embodiment of the invention, an increase in the level of 3-chlorotyrosine or 3-bromotyrosine from the normal level in a sample of body fluid or tissue is indicative of early sepsis or infection. In another embodiment of the invention, the level of 3-chlorotyrosine or 3-bromotyrosine is measured or monitored to determine the response to therapeutic treatment of the infective condition in which a reduction in the level that existed prior to the treatment is an early sign or indication that the treatment is working in vivo. In a preferred embodiment, the method of the invention is illustrated in a clinically relevant mouse model of sepsis.

Claims

1. A method for detecting conditions indicative of sepsis comprising determining the level of 3-chlorotyrosine or 3-bromotyrosine in a sample of body fluid or tissue withdrawn from a patient suspected of having an infection in which a level elevated from the normal level is indicative of early infection or sepsis.

2. The method of claim 1 in which the level of 3-chlorotyrosine or 3-bromotyrosine is determined or monitored prior to and after the treatment of said patient with therapeutic treatment of infection.

3. The method of claim 1 in which the level of 3-chlorotyrosine is determined.

4. The method of claim 2 in which the level of 3-chlorotyrosine is determined.

5. The method of claim 1 in which the level of 3-bromotyrosine is determined.

6. The method of claim 2 in which the level of 3-bromotyrosine is determined.

7. The method of any of claims 1-6 in which the level of 3-chlorotyrosine or 3-bromotyrosine is determined by gas chromatography and mass spectrometry.